Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) (NCT06710132)

🧪 Interventions in This Study

• M9140 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (81 Sites)

Showing the first 25 of 81 sites.

• University of California - Los Angeles - 300208353 — Santa Monica, California
• Providence Medical Foundation — Santa Rosa, California
• Georgetown University - Lombardi Comprehensive Cancer Center - 1134847 — Washington D.C., District of Columbia
• D&H Cancer Research Center — Margate, Florida
• Prisma Health Cancer Institute, ITOR, CRU — Greenville, South Carolina
• Baptist Cancer Center — Memphis, Tennessee
• The University of Texas MD Anderson Cancer Center — Houston, Texas
• NEXT Virginia — Fairfax, Virginia
• Flinders Medical Centre — Bedford Park,
• Nepean Cancer Care Centre — Kingswood,
• Mater Misericordiae Ltd - PARENT — South Brisbane,
• Macquarie University Hospital - PARENT — Sydney,
• Ordensklinikum Linz Krankenhaus der Elisabethinen Linz - Pneumology — Linz,
• LKH - Universitätsklinikum der PMU Salzburg - Innere Med III/Hämatologie und Onkologie — Salzburg,
• Medical University of Vienna - Department of Internal Medicine — Vienna,
• Anhui Provincial Cancer Hospital — Hefei, Anhui
• Beijing Cancer Hospital — Beijing, Beijing Municipality
• Sun Yat-sen University Cancer Center — Guangzhou, Guangzhou
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hebei
• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang
• Xiangya Hospital, Central South University — Changsha, Hu'nan
• Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology — Wuhan, Hubei
• Sichuan Cancer Hospital — Chengdu, Sichuan
• West China Hospital, Sichuan University — Chengdu, Sichuan
• Sir Run Run Shaw Hospital, Zhejiang University School of Medicine - Department of Oncology Surgery — Hangzhou, Zhejiang

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumors

• Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
• Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
• A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
• Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
• Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona

Explore by condition: All Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.